logo-loader
viewEquiniti

Equiniti crumbles as it forecasts earnings at bottom end of estimates

The gloomy earnings forecast came despite the outsourcer also predicting revenues for 2019 will be at "the upper end of market expectations"

Equiniti - Equiniti crumbles as it forecasts earnings at bottom end of estimates
The gloomy earnings forecast was blamed on weakness in “higher margin UK corporate activity”

Equinti Group PLC (LON:EQN) shares sank on Tuesday after the outsourcing group said its 2019 earnings will be at the lower end of estimates despite revenues hitting the top level of forecasts.

In a trading update for the period from 1 July to 18 November, the FTSE 250 group said weakness in “higher margin UK corporate activity” meant its underlying EBITDA will be “towards the lower end” of the £136-£142mln forecast despite revenues being “at the upper end of market expectations” based on a range of between £550-£567mln.

READ: Equiniti profits climb as US growth helps offset UK pensions challenges

Looking ahead, Equiniti expects “uncertainty in the macro environment to continue”, although the company stressed that it was well positioned and expected further organic growth in the UK and “accelerated growth” in the US.

That did little to reassure investors, however, with the stock slumping 8.4% to 208.4p in early deals.

In a note, analysts at Peel Hunt cut their profit forecasts for Equiniti by 7% to £77.2mln as a result of the earnings warning, however, they retained their ‘buy’ rating and 242p target price.

Quick facts: Equiniti

Price: 214.4 GBX

LSE:EQN
Market: LSE
Market Cap: £781.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

32 minutes ago

RNS

Director/PDMR Shareholding

6 days, 23 hours ago

Total Voting Rights

2 weeks, 3 days ago

Director/PDMR Shareholding

3 weeks, 5 days ago

Director/PDMR Shareholding

3 weeks, 5 days ago

Director/PDMR Shareholding

3 weeks, 6 days ago

TRADING UPDATE

3 weeks, 6 days ago

2 min read